Kepler Capital Markets set a €110.00 ($127.91) target price on Merck KGaA (FRA:MRK) in a report released on Thursday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

A number of other equities analysts have also commented on MRK. Goldman Sachs Group set a €95.00 ($110.47) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Thursday, March 7th. Deutsche Bank set a €97.00 ($112.79) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research note on Monday, March 11th. HSBC set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, March 11th. DZ Bank reissued a neutral rating on shares of Merck KGaA in a research note on Monday, November 26th. Finally, Warburg Research set a €103.00 ($119.77) target price on shares of Merck KGaA and gave the company a neutral rating in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and six have given a buy rating to the company. The company has an average rating of Hold and an average target price of €100.00 ($116.28).

Merck KGaA stock opened at €98.36 ($114.37) on Thursday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What are no-load funds?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.